HomeCompareHBMHF vs VICI

HBMHF vs VICI: Dividend Comparison 2026

HBMHF yields 128.21% · VICI yields 6.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HBMHF wins by $10.63M in total portfolio value
10 years
HBMHF
HBMHF
● Live price
128.21%
Share price
$1.56
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11.60M
Annual income
$4,575,129.27
Full HBMHF calculator →
VICI
VICI Properties Inc.
● Live price
6.52%
Share price
$27.32
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$966.2K
Annual income
$607,376.13
Full VICI calculator →

Portfolio growth — HBMHF vs VICI

📍 HBMHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHBMHFVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HBMHF + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HBMHF pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HBMHF
Annual income on $10K today (after 15% tax)
$10,897.44/yr
After 10yr DRIP, annual income (after tax)
$3,888,859.88/yr
VICI
Annual income on $10K today (after 15% tax)
$554.58/yr
After 10yr DRIP, annual income (after tax)
$516,269.71/yr
At 15% tax rate, HBMHF beats the other by $3,372,590.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HBMHF + VICI for your $10,000?

HBMHF: 50%VICI: 50%
100% VICI50/50100% HBMHF
Portfolio after 10yr
$6.28M
Annual income
$2,591,252.69/yr
Blended yield
41.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

HBMHF
No analyst data
Altman Z
8.0
Piotroski
7/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+15.7% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HBMHF buys
0
VICI buys
0
No recent congressional trades found for HBMHF or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHBMHFVICI
Forward yield128.21%6.52%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$11.60M$966.2K
Annual income after 10y$4,575,129.27$607,376.13
Total dividends collected$10.60M$926.2K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: HBMHF vs VICI ($10,000, DRIP)

YearHBMHF PortfolioHBMHF Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$23,521$12,820.51$11,361$941.49+$12.2KHBMHF
2$53,349$28,181.78$13,320$1,481.32+$40.0KHBMHF
3$116,823$59,739.54$16,284$2,405.01+$100.5KHBMHF
4$247,259$122,259.11$21,040$4,071.78+$226.2KHBMHF
5$506,405$241,837.18$29,209$7,285.49+$477.2KHBMHF
6$1,004,750$462,896.88$44,443$14,006.51+$960.3KHBMHF
7$1,933,425$858,342.70$75,822$29,512.55+$1.86MHBMHF
8$3,612,406$1,543,641.03$148,733$69,726.75+$3.46MHBMHF
9$6,560,727$2,695,452.74$344,394$189,413.75+$6.22MHBMHF
10$11,595,107$4,575,129.27$966,234$607,376.13+$10.63MHBMHF

HBMHF vs VICI: Complete Analysis 2026

HBMHFStock

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.

Full HBMHF Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this HBMHF vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HBMHF vs SCHDHBMHF vs JEPIHBMHF vs OHBMHF vs KOHBMHF vs MAINHBMHF vs NNNHBMHF vs EPRTHBMHF vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.